<DOC>
	<DOCNO>NCT01009918</DOCNO>
	<brief_summary>RATIONALE : Lisinopril Coreg CR® , may help reduce side effect cause trastuzumab . It yet know whether lisinopril Coreg CR® effective placebo reduce side effect cause trastuzumab . PURPOSE : This phase II trial study lisinopril Coreg CR® see well work compare placebo reduce side effect patient HER2-positive breast cancer receive trastuzumab .</brief_summary>
	<brief_title>Lisinopril Coreg CR® Reducing Side Effects Women With Breast Cancer Receiving Trastuzumab</brief_title>
	<detailed_description>OBJECTIVES : Primary - The primary objective study determine administration lisinopril Coreg CR® , compare placebo , reduce incidence trastuzumab-induced cardiotoxicity , measure LVEF , patient receive adjuvant , neoadjuvant , therapy HER2 positive breast cancer . Secondary - To determine whether subject randomize active agent few interruption trastuzumab therapy due cardiomyopathy . - To determine whether treatment effect consistent anthracycline nonanthracycline patient cohort - To compare change HRQL among treatment group study intervention - To evaluate long term effect prevention cardiomyopathy impact HRQL either study agent - To compare predictive value troponin I BNP identification trastuzumab-induced cardiotoxicity OUTLINE : This multicenter study . Patients stratify accord chemotherapy comprising anthracycline ( yes v ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive oral lisinopril daily . - Arm II : Patients receive oral Coreg CR® daily . - Arm III : Patients receive oral placebo daily . In arm , study treatment begin first dose trastuzumab continue 52 week end trastuzumab therapy . Quality life assess use EORTC QLQ-C30 questionnaire baseline , 52 week ( end trastuzumab therapy ) , 18 24 month ( 6 12 month completion trastuzumab ) . After completion study treatment , patient follow 3 , 6 , 9 , 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>INCLUSION CRITERIA Males Females ≥ 18 year old diagnose HER2 positive breast cancer Scheduled receive neoadjuvant adjuvant trastuzumab ( Herceptin® ) therapy ( anthracyclinecontaining regimen permit ) . Patients receive Herceptin® chemotherapy permit eligibility workup . Taxanes permit . Trastuzumab ( Herceptin® ) therapy may give primary chemotherapy . Pertuzumab may use conjunction trastuzumab . Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % MUGA scan echocardiogram Adequate renal function administration trastuzumabcontaining chemotherapy regimen . Sitting systolic blood pressure &gt; 90 mm Hg Pulse ≥ 60 beats/minute Not pregnant breastfeed Female patient childbearing potential , sexually active , must negative pregnancy test start study Both men woman must willing use effective contraception study . Teratogenicity document active study agent Able swallow capsule EXCLUSION CRITERIA : Patients metastatic disease Prior treatment trastuzumab anthracyclines prior chemotherapy regimen Current treatment angiotensin convert enzyme ( ACE ) inhibitor , angiotensin receptor blocker ( ARBs ) , losartan , βblockers digoxin Known cardiac history : heart failure , myocardial infarction , radiationinduced cardiac dysfunction Known allergy either ACE inhibitor βblockers History bronchial asthma relate bronchospastic condition Hereditary idiopathic angioedema History severe hypersensitivity reaction drug cause , i.e . bee sting This protocol exclude patient participate investigational study . Refer local IRB guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cardiac toxicity</keyword>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>